| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2005;79:248-253
© 2005 The Society of Thoracic Surgeons
a Department of Surgery II
b Department of Pathology, Nippon Medical School, Tokyo, Japan
Accepted for publication June 25, 2004.
* Address reprint requests to Dr Hirai, Department of Surgery II, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan (E-mail: ky-hirai{at}nms.ac.jp).
BACKGROUND: Maspin is a serpin protease inhibitor, which is known to suppress tumor progression in breast cancer and to be regulated by wild-type p53. This study was performed to elucidate the biologic significance of maspin expression in non–small cell lung cancer.
METHODS: To investigate whether maspin is involved in progression, clinicopathologic features, and prognosis of non–small cell lung cancer, we performed an immunohistochemical study using antimaspin antibody and identified the presence of maspin messenger ribonucleic acid in cancerous and noncancerous tissues by reverse transcription–polymerase chain reaction analysis. In addition, we evaluated p53 expression immunohistochemically on the serial sections.
RESULTS: Most adenocarcinoma and squamous cell carcinoma showed cytoplasmic staining pattern. The cytoplasmic positive rate was 77.8% (42 of 54 specimens) for the stage III group, and 36.2% (21 of 58 specimens) for the stage I group (p < 0.0001). Three-year survival rates after operation were 30.8% for the maspin-positive group and 71.1% for the maspin-negative group (p = 0.007). In multivariate analysis, immunohistochemical maspin expression in patients with non–small cell lung cancer was an independent prognostic factor for overall survival. No correlation between maspin and p53 expression in cancer cells could be observed. There was an average fourfold increase in maspin messenger ribonucleic acid levels in cancerous tissues compared with those of noncancerous tissues, and stage III cases exhibited significantly higher maspin messenger ribonucleic acid levels than stage I cases (p = 0.003).
CONCLUSIONS: The results of this study suggest that overexpression of maspin in cytoplasm may be a useful marker of tumor progression and unfavorable prognosis for overall survival in some patients with non–small cell lung cancer. Furthermore, maspin expression in cytoplasm appears to be unaffected by p53.
This article has been cited by other articles:
|
|
 |
|
  M. Woenckhaus, L. Bubendorf, P. Dalquen, J. Foerster, H. Blaszyk, M. Mirlacher, M. Soler, W. Dietmaier, G. Sauter, A. Hartmann, et al. Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer J. Clin. Pathol., May 1, 2007; 60(5): 483 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Tsoli, P. K Tsantoulis, A. Papalambros, B. Perunovic, D. England, D. A Rawlands, G. M Reynolds, D. Vlachodimitropoulos, S. L Morgan, C. A Spiliopoulou, et al. Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer J. Clin. Pathol., March 1, 2007; 60(3): 261 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nakagawa, H. Katakura, M. Adachi, K. Takenaka, K. Yanagihara, Y. Otake, H. Wada, and F. Tanaka Maspin Expression and Its Clinical Significance in Non-Small Cell Lung Cancer Ann. Surg. Oncol., November 1, 2006; 13(11): 1517 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nazarenko, G. Kristiansen, S. Fonfara, R. Guenther, C. Gieseler, W. Kemmner, R. Schafer, I. Petersen, and C. Sers H-REV107-1 Stimulates Growth in Non-Small Cell Lung Carcinomas via the Activation of Mitogenic Signaling Am. J. Pathol., October 1, 2006; 169(4): 1427 - 1439. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
